123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: A SPECT semiquantitative study

Luca Filippi, Carlo Manni, Mariangela Pierantozzi, Livia Brusa, Roberta Danieli, Paolo Stanzione, Orazio Schillaci

Research output: Contribution to journalArticlepeer-review


BACKGROUND AND AIM: It is still debated whether or not 123I-FP- CIT single photon emission computerized tomography (SPECT) is able to differentiate between Parkinson's disease and progressive supranuclear palsy (PSP). Our aim was to use SPECT semiquantitative analysis to assess the capacity of 123I-FP-CIT to characterize Parkinson's disease versus PSP. PATIENTS AND METHODS: Twenty-one Parkinson's disease patients, 15 disease duration- and age-matched PSP patients and 20 age-matched healthy controls were included in this study. SPECT imaging was always performed at 4 h post-injection. The ratios of striatal (S) to non-specific occipital (O) binding for the entire striatum (S/O), caudate nuclei (C/O), putamina (P/O) were calculated in both the basal ganglia. The asymmetric index (AI) for the whole striatum was also calculated for Parkinson's disease and PSP. RESULTS: Compared to healthy controls, S/O, C/O and P/O were significantly reduced (P123I-FP-CIT SPECT is clinically useful for detecting nigrostriatal degeneration both in Parkinson's disease and PSP. Moreover, in our series, semiquantitative analysis using 123I-FP-CIT SPECT allowed Parkinson's disease and PSP to be discriminated because PSP patients presented a more severe and symmetric dopamine transporter loss, and the results for S/O were more accurate.

Original languageEnglish
Pages (from-to)381-386
Number of pages6
JournalNuclear Medicine Communications
Issue number4
Publication statusPublished - Apr 2006


  • I-FP-CIT
  • Dopamine transporter imaging
  • Parkinson's disease
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology


Dive into the research topics of '123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: A SPECT semiquantitative study'. Together they form a unique fingerprint.

Cite this